Healthcare

Mobile-health Network Solutions Ranked Number 41 in Financial Times Listing of 500 High-growth Asia-Pacific Companies

SINGAPORE, April 17, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR), a leading telehealth solutions provider in Singapore, today…

3 months ago

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to presentSOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke…

3 months ago

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

New patent-protected, central recruitment leverages the Science 37 Metasite™ to accelerate enrollment and dramatically reduce site burdenRESEARCH TRIANGLE PARK, N.C.,…

3 months ago

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing…

3 months ago

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE…

3 months ago

Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules

Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic…

3 months ago

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing…

3 months ago

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a…

3 months ago

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between…

3 months ago